Paper41537239
Characterizing clinical toxicity in cancer combination therapies.
Wong AM and 2 others. Bioinformatics, 2026. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. Characterizing clinical toxicity in cancer combination therapies. Papers, record 41537239. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41537239
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Neoplasms | Major topic |
| Antineoplastic Agents | Major topic |
| Computational Biology | Major topic |
| Antineoplastic Combined Chemotherapy Protocols | Major topic |
| Humans | |
| Algorithms | |
| Drug Synergism | |
| Drug Interactions |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| David & Lucile Packard Fellowship for Science and Engineering | PubMed |
Source PubMed
References38
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 37467066 | DeepTraSynergy: drug combinations using multimodal deep learning with transformers. | Bioinformatics | 2023 | https://conductscience.org/library/papers/37467066 | PubMed |
| 2 | 29245013 | Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. | Cell | 2017 | https://conductscience.org/library/papers/29245013 | PubMed |
| 3 | 26983881 | An Unbiased Oncology Compound Screen to Identify Novel Combination Strategies. | Mol Cancer Ther | 2016 | https://conductscience.org/library/papers/26983881 | PubMed |
| 4 | 32015543 | SciPy 1.0: fundamental algorithms for scientific computing in Python. | Nat Methods | 2020 | https://conductscience.org/library/papers/32015543 | PubMed |
| 5 | 40028209 | Prediction of cancer cell line-specific synergistic drug combinations based on multi-omics data. | PeerJ | 2025 | https://conductscience.org/library/papers/40028209 | PubMed |
| 6 | 36370105 | The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. | Nucleic Acids Res | 2023 | https://conductscience.org/library/papers/36370105 | PubMed |
| 7 | 24500406 | High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. | Sci Transl Med | 2014 | https://conductscience.org/library/papers/24500406 | PubMed |
| 8 | 38514966 | CFSSynergy: Combining Feature-Based and Similarity-Based Methods for Drug Synergy Prediction. | J Chem Inf Model | 2024 | https://conductscience.org/library/papers/38514966 | PubMed |
| 9 | 40088336 | Predicting Synergistic Drug Combinations Based on Fusion of Cell and Drug Molecular Structures. | Interdiscip Sci | 2025 | https://conductscience.org/library/papers/40088336 | PubMed |
| 10 | 37974028 | Additivity predicts the efficacy of most approved combination therapies for advanced cancer. | Nat Cancer | 2023 | https://conductscience.org/library/papers/37974028 | PubMed |
| 11 | 36562722 | CCSynergy: an integrative deep-learning framework enabling context-aware prediction of anti-cancer drug synergy. | Brief Bioinform | 2023 | https://conductscience.org/library/papers/36562722 | PubMed |
| 12 | 21051364 | The proof and measurement of association between two things. | Int J Epidemiol | 2010 | https://conductscience.org/library/papers/21051364 | PubMed |
| 13 | 38398099 | Reasons for Treatment Discontinuation and Their Effect on Outcomes of Immunotherapy in Southwest Finland: A Retrospective, Real-World Cohort Study. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38398099 | PubMed |
| 14 | 27723879 | Failure of Investigational Drugs in Late-Stage Clinical Development and Publication of Trial Results. | JAMA Intern Med | 2016 | https://conductscience.org/library/papers/27723879 | PubMed |
| 15 | 34634800 | DDInter: an online drug-drug interaction database towards improving clinical decision-making and patient safety. | Nucleic Acids Res | 2022 | https://conductscience.org/library/papers/34634800 | PubMed |
| 16 | 32012154 | SynToxProfiler: An interactive analysis of drug combination synergy, toxicity and efficacy. | PLoS Comput Biol | 2020 | https://conductscience.org/library/papers/32012154 | PubMed |
| 17 | 30867426 | Network-based prediction of drug combinations. | Nat Commun | 2019 | https://conductscience.org/library/papers/30867426 | PubMed |
| 18 | 34079102 | Planning for tomorrow: global cancer incidence and the role of prevention 2020-2070. | Nat Rev Clin Oncol | 2021 | https://conductscience.org/library/papers/34079102 | PubMed |
| 19 | 39552041 | UniProt: the Universal Protein Knowledgebase in 2025. | Nucleic Acids Res | 2025 | https://conductscience.org/library/papers/39552041 | PubMed |
| 20 | 34472609 | GraphSynergy: a network-inspired deep learning model for anticancer drug combination prediction. | J Am Med Inform Assoc | 2021 | https://conductscience.org/library/papers/34472609 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41537239
GET https://conductscience.org/api/papers/v1/41537239/references?page=2